Ines Pires da Silva

Has grant

Senior Lecturer

University of Sydney

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ines Pires da Silva is a Senior Lecturer at the University of Sydney, Australia. Her research primarily focuses on cancer immunotherapy, particularly in the context of melanoma and its associated immune microenvironments. Recent publications include studies on clinical outcomes of patients with advanced melanoma and the impact of tumor microenvironments on treatment responses. She also explores innovative clinical trial designs to enhance skin cancer research.

Recent Grants

Grant: Close

Liver metastases: a niche of resistance and of therapeutic opportunities for all cancers.

Open Date: 2023-01-01

Close Date: 2025-12-01

Grant: Close

Matching optimal drug therapy to overcome organ-specific resistance to standard immunotherapy in melanoma

Open Date: 2022-07-01

Close Date: 2024-06-01

Grant: Close

Patterns and management of progression on 1st line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.

Open Date: 2021-06-01

Close Date:

Grant: Close

Clinical models predictive of response and survival in advanced melanoma patients treated with anti-PD1 monotherapy or in combination with anti-CTLA-4

Open Date: 2021-04-01

Close Date:

Grant: Close

Risk factors of immune-checkpoint inhibitors mediated liver, gastrointestinal, endocrine and skin toxicity (ICEMELT).

Open Date: 2021-01-01

Close Date: 2022-12-01

Articles (12)

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Howard Gurney

Macquarie University

AUSTRALIA

Ines Pires da Silva

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (12)

Transforming Clinical Trials in Skin Cancer Research: Exploring the Potential of Flexible and Innovative Designs

Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy

Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites

The effect of organ-specific tumor microenvironments on response patterns to immunotherapy.

Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis.

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome.

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

Collaborators (16)

Howard Gurney

Ana Arance

Serigne N. Lô

Nurudeen Adegoke

John Thompson

Ellis Patrick

Jordan Conway

Mark Read

Jian Tan

Manoj Chelvanambi

Elena Shklovskaya

Natalie Cook

Felix Marsh‐Wakefield

Rebecca Simpson

Helen Rizos

Lauren Julia Brown

Make your next move.